Kush M. Parmar

Kush Parmar currently serves as CEO and member of the board of directors of Ensoma. As managing partner at 5AM Ventures, he currently serves on the board of directors of Akouos, Entrada Therapeutics, Homology Medicines, Rallybio and Vor Biopharma. Previously, Kush served as board member or observer for Achaogen, Arvinas, Audentes Therapeutics (acquired by Astellas), Envoy Therapeutics (acquired by Takeda) and scPharmaceuticals, as well as acting vice president of strategy and corporate development at Novira (acquired by Johnson & Johnson).

Kush currently serves on the advisory boards of Harvard Medical School, Penn Medicine, Princeton University’s Department of Molecular Biology and the Grace Science Foundation. He is a fellow of the Society of Kauffman Fellows.

Prior to 5AM, Kush was an NIH-sponsored M.D./Ph.D. physician scientist fellow at Harvard Medical School in the Harvard-MIT Health Sciences and Technology Program. He completed clinical clerkships at the Massachusetts General and Brigham and Women’s Hospitals.

Kush holds an A.B. in molecular biology and medieval studies from Princeton University, a Ph.D. in experimental pathology from Harvard University and an M.D. from Harvard Medical School.